NCT03316417

Study of Adverse Renal Effects of Immune Checkpoints Inhibitors

Adverse Renal Effects of Immune Checkpoints Inhibitors (Nivolumab, Pembrolizumab, Atezolizumab and Ipilimumab) in Clinical Practice: a Large Monocentric Prospective Study

• Status: Completed
• Phase: —
• Study type: Observational
• Enrollment: 353 (actual)
• Sponsor: Hospices Civils de Lyon · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

Renal toxic events related to Immune Checkpoints Inhibitors therapy (Nivolumab, Pembrolizumab, Atezolizumab and Ipilimumab) have been recently reported. These were immune-allergic acute interstitial nephritis. However, no systematic study has ever focused on renal adverse effects. The investigators study here the evolution of renal function and the occurrence of nephrological events in a large monocentric cohort of patients treated with Immune Checkpoints Inhibitors in the Centre Hospitalier Lyon Sud. Nephrological parameters based on Serum Creatinine (SCr), estimate Glomerular Filtration Rate (eGFR) and urinary sediment are monitored. The aim of the study is to determine the incidence of renal events due to Immune Checkpoint Inhibitor treatment, particularly Acute Kidney Injury, (AKI) and identify the clinical presentation, histological description and risk factors.

Conditions

• Adverse Effect
• Renal Toxicity

Interventions

Type	Name	Description
OTHER	Renal Tolerance to Immunotherapy	The main objective is to describe the renal tolerance of these innovative therapies within a population homogeneous of patients.

Timeline

• Start date: 2017-10-27
• Primary completion: 2017-10-27
• Completion: 2017-10-27
• First posted: 2017-10-20
• Last updated: 2019-08-14

Locations

1 site across 1 country: France